The issue, brought on by a manufacturing defect, has been linked to two serious injuries. The FDA shared an early alert about the situation as it continues its investigation. 

It was a relatively small study, and patients were only followed for six months, but these late-breaking data out of ESC Congress 2026 give care teams a lot to consider. 

The new guidelines, published in European Heart Journal and presented at ESC Congress 2026, show just how much heart failure care has evolved in recent years.

The popular diabetes drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.

Less than a year after investing heavily in Minnesota-based Anteris Technologies, Medtronic has announced a new strategic investment in Pi-Cardia. The TAVR technology at the heart of this investment is Pi-Cardia's FDA-approved ShortCut device. 

Each system is powered by GE HealthCare's cSound imaging architecture and includes advanced AI capabilities.

More than 95% of congenital heart patients now survive into adulthood, leaving clinicians with much more ground to cover than ever before. Providing high-quality care for these patients requires specialty care as well as collaborations with general cardiologists.

Boston Scientific is warning clinicians about an ongoing safety concern with its LUX-Dx family of insertable cardiac monitors. No devices need to be returned or replaced, but the FDA did finalize a Class II recall. 

The question is further complicated by possibly needing different thresholds for pregnant, premenopausal, and postmenopausal woman.

Many patients who need TAVR also present with coronary artery disease. According to new data presented at ESC Congress 2026, performing TAVR first is noninferior to performing PCI first.